Silexion Therapeutics (SLXN) Stock Price, News & Analysis

Company Overview

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.

Key Stats

• Today's Range: $6.55 to $7.25
• 50-Day Range: $7.11 to $14.94
• 52-Week Range: $6.55 to $256.50
• Volume: 26,814 shs
• Average Volume: 429,962 shs
• Market Capitalization: $3.97 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $75.00
• Consensus Rating: Buy

Silexion Therapeutics Stock Analysis - MarketRank™

Silexion Therapeutics scored higher than 26% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Silexion Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Silexion Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Silexion Therapeutics has a P/B Ratio of 32.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for SLXN.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Silexion Therapeutics does not currently pay a dividend.

Dividend Growth

Silexion Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for SLXN.

News and Social Media

• Score: 1.6 / 5
• News Sentiment: N/A

News Sentiment

Silexion Therapeutics has a news sentiment score of -0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Silexion Therapeutics this week, compared to 1 article on an average week.

Search Interest

Only 6 people have searched for SLXN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

1 people have added Silexion Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Silexion Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 6.00% of the stock of Silexion Therapeutics is held by insiders.

Percentage Held by Institutions

Only 10.95% of the stock of Silexion Therapeutics is held by institutions.

SLXN Stock Analysis - Frequently Asked Questions

How have SLXN shares performed this year?

Silexion Therapeutics' stock was trading at $30.15 on January 1st, 2025. Since then, SLXN shares have decreased by 77.4% and is now trading at $6.8250.

How were Silexion Therapeutics' earnings last quarter?

Silexion Therapeutics Corp (NASDAQ:SLXN) announced its quarterly earnings data on Tuesday, August, 12th. The company reported ($4.32) earnings per share for the quarter, missing analysts' consensus estimates of ($3.15) by $1.17.

When did Silexion Therapeutics' stock split?

Shares of Silexion Therapeutics reverse split on Sunday, July 27th 2025.The 1-15 reverse split was announced on Sunday, July 27th 2025. The number of shares owned by shareholders was adjusted after the market closes on Sunday, July 27th 2025. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

How do I buy shares of Silexion Therapeutics?

Shares of SLXN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Silexion Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Silexion Therapeutics investors own include Arch Capital Group (ACGL), Adobe (ADBE), Analog Devices (ADI), Alnylam Pharmaceuticals (ALNY), Amgen (AMGN), AstraZeneca (AZN) and Baidu (BIDU).

Company Calendar

• Last Earnings: 8/12/2025
• Today: 8/20/2025
• Next Earnings (Estimated): 9/04/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SLXN
• Previous Symbol: NASDAQ:SLXN
• CIK: 2022416
• Web: silexion.com
• Phone: 972-2-674-3430
• Fax: 212-572-6395
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Silexion Therapeutics: $75.00
• High Price Target: $75.00
• Low Price Target: $75.00
• Potential Upside/Downside: +954.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$16.44 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -355.74%

Debt

• Debt-to-Equity Ratio: 26.58
• Current Ratio: 2.44
• Quick Ratio: 2.44

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.21 per share
• Price / Book: 33.86

Miscellaneous

• Outstanding Shares: 580,000
• Free Float: 545,000
• Market Cap: $4.12 million
• Optionable: N/A
• Beta: 0.08